S&P 500   5,253.88 (+0.10%)
DOW   39,767.51 (+0.02%)
QQQ   444.87 (+0.01%)
AAPL   170.81 (-1.44%)
MSFT   420.69 (-0.18%)
META   489.70 (-0.84%)
GOOGL   150.41 (-0.30%)
AMZN   180.82 (+0.55%)
TSLA   176.92 (-1.62%)
NVDA   908.14 (+0.62%)
NIO   4.63 (-0.86%)
AMD   182.99 (+1.89%)
BABA   72.40 (+1.13%)
T   17.58 (+0.17%)
F   13.19 (+1.00%)
MU   118.42 (-0.60%)
CGC   9.11 (-4.61%)
GE   175.56 (-2.53%)
DIS   122.20 (+1.01%)
AMC   3.74 (-13.82%)
PFE   27.86 (+0.29%)
PYPL   66.94 (+0.56%)
XOM   115.40 (+0.37%)
S&P 500   5,253.88 (+0.10%)
DOW   39,767.51 (+0.02%)
QQQ   444.87 (+0.01%)
AAPL   170.81 (-1.44%)
MSFT   420.69 (-0.18%)
META   489.70 (-0.84%)
GOOGL   150.41 (-0.30%)
AMZN   180.82 (+0.55%)
TSLA   176.92 (-1.62%)
NVDA   908.14 (+0.62%)
NIO   4.63 (-0.86%)
AMD   182.99 (+1.89%)
BABA   72.40 (+1.13%)
T   17.58 (+0.17%)
F   13.19 (+1.00%)
MU   118.42 (-0.60%)
CGC   9.11 (-4.61%)
GE   175.56 (-2.53%)
DIS   122.20 (+1.01%)
AMC   3.74 (-13.82%)
PFE   27.86 (+0.29%)
PYPL   66.94 (+0.56%)
XOM   115.40 (+0.37%)
S&P 500   5,253.88 (+0.10%)
DOW   39,767.51 (+0.02%)
QQQ   444.87 (+0.01%)
AAPL   170.81 (-1.44%)
MSFT   420.69 (-0.18%)
META   489.70 (-0.84%)
GOOGL   150.41 (-0.30%)
AMZN   180.82 (+0.55%)
TSLA   176.92 (-1.62%)
NVDA   908.14 (+0.62%)
NIO   4.63 (-0.86%)
AMD   182.99 (+1.89%)
BABA   72.40 (+1.13%)
T   17.58 (+0.17%)
F   13.19 (+1.00%)
MU   118.42 (-0.60%)
CGC   9.11 (-4.61%)
GE   175.56 (-2.53%)
DIS   122.20 (+1.01%)
AMC   3.74 (-13.82%)
PFE   27.86 (+0.29%)
PYPL   66.94 (+0.56%)
XOM   115.40 (+0.37%)
S&P 500   5,253.88 (+0.10%)
DOW   39,767.51 (+0.02%)
QQQ   444.87 (+0.01%)
AAPL   170.81 (-1.44%)
MSFT   420.69 (-0.18%)
META   489.70 (-0.84%)
GOOGL   150.41 (-0.30%)
AMZN   180.82 (+0.55%)
TSLA   176.92 (-1.62%)
NVDA   908.14 (+0.62%)
NIO   4.63 (-0.86%)
AMD   182.99 (+1.89%)
BABA   72.40 (+1.13%)
T   17.58 (+0.17%)
F   13.19 (+1.00%)
MU   118.42 (-0.60%)
CGC   9.11 (-4.61%)
GE   175.56 (-2.53%)
DIS   122.20 (+1.01%)
AMC   3.74 (-13.82%)
PFE   27.86 (+0.29%)
PYPL   66.94 (+0.56%)
XOM   115.40 (+0.37%)
NYSEAMERICAN:VNRX

VolitionRx (VNRX) Stock Price, News & Analysis

$0.78
+0.04 (+4.98%)
(As of 10:45 AM ET)
Today's Range
$0.73
$0.79
50-Day Range
N/A
52-Week Range
$0.55
$2.10
Volume
88,839 shs
Average Volume
189,062 shs
Market Capitalization
$49.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.00

VolitionRx MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
156.4% Upside
$2.00 Price Target
Short Interest
Healthy
0.77% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.50) to ($0.33) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.89 out of 5 stars

VNRX stock logo

About VolitionRx Stock (NYSEAMERICAN:VNRX)

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 worldwide. It offers Nu.Q Vet cancer screening blood test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer that detect cancer; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company is based in Henderson, Nevada.

VNRX Stock Price History

VNRX Stock News Headlines

Buy Friday, Sell Monday, No Exceptions
Every week traders grind it out Monday through Friday… But neglect trading Friday to Monday… Or… “over the weekend” As one professional trader explains, trading over the weekend is one of the most forgiving strategies you can use today. It allows him to sidestep a lot of the midweek volatility. Yet, gives him the opportunity to target some of the markets biggest stock moves. Just recently, he posted a trade on Nordstrom… The trade was published at 3pm on a Friday afternoon and by Monday morning the trade more than doubled.
Volition Issues Business Review 2023
The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
Cantor Fitzgerald Reaffirms Their Buy Rating on VolitionRX (VNRX)
US Ambassador Adler visits Belgian Volition
VolitionRx holds roundtable on sepsis management
See More Headlines
Receive VNRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VolitionRx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostics & Research
Sub-Industry
N/A
Current Symbol
NYSEAMERICAN:VNRX
Previous Symbol
NYSEMKT:VNRX
CIK
N/A
Employees
114
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.00
High Stock Price Target
$2.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+169.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-30,270,000.00
Net Margins
-9,158.31%
Pretax Margin
-9,257.43%
Return on Equity
-15,493.47%

Debt

Sales & Book Value

Annual Sales
$310,000.00
Book Value
($0.05) per share

Miscellaneous

Free Float
53,450,000
Market Cap
$46.94 million
Optionable
Not Optionable
Beta
1.59
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. Martin Charles Faulkes Ph.D. (Age 80)
    Executive Chairman
    Comp: $227.63k
  • Mr. Cameron Reynolds MBA (Age 53)
    Founder, CEO, President & Director
    Comp: $538.66k
  • Mr. Terig Hughes (Age 54)
    CFO & Treasurer
    Comp: $338.74k
  • Dr. Gaetan Michel Ph.D. (Age 51)
    Chief Operating Officer
    Comp: $445.06k
  • Dr. Jacob Vincent Micallef MBA (Age 68)
    Ph.D., Chief Scientific Officer
    Comp: $571.55k

VNRX Stock Analysis - Frequently Asked Questions

Should I buy or sell VolitionRx stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for VolitionRx in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" VNRX shares.
View VNRX analyst ratings
or view top-rated stocks.

What is VolitionRx's stock price target for 2024?

1 equities research analysts have issued 1-year target prices for VolitionRx's shares. Their VNRX share price targets range from $2.00 to $2.00. On average, they predict the company's share price to reach $2.00 in the next year. This suggests a possible upside of 156.4% from the stock's current price.
View analysts price targets for VNRX
or view top-rated stocks among Wall Street analysts.

Are investors shorting VolitionRx?

VolitionRx saw a decline in short interest in February. As of February 15th, there was short interest totaling 479,200 shares, a decline of 19.9% from the January 31st total of 598,500 shares. Based on an average trading volume of 220,500 shares, the short-interest ratio is presently 2.2 days.
View VolitionRx's Short Interest
.

How were VolitionRx's earnings last quarter?

VolitionRx Limited (NYSEAMERICAN:VNRX) announced its earnings results on Wednesday, November, 10th. The medical research company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.02. The medical research company earned $0.03 million during the quarter, compared to analysts' expectations of $0.03 million. VolitionRx had a negative net margin of 9,158.31% and a negative trailing twelve-month return on equity of 15,493.47%.

What other stocks do shareholders of VolitionRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VolitionRx investors own include Chesapeake Energy (CHKAQ), Bausch Health Companies (BHC), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL), CRISPR Therapeutics (CRSP), TherapeuticsMD (TXMD), ADMA Biologics (ADMA) and Bausch Health Companies (BHC).

How do I buy shares of VolitionRx?

Shares of VNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:VNRX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners